Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
Duchenne muscular dystrophy is a rare, progressive, muscle-wasting disease leading to severe disability and premature death. Treatment is currently symptomatic, but several experimental therapies are in development. Implemented care standards, validated outcome measures correlating with clinical ben...
Main Authors: | Straub, V, Balabanov, P, Bushby, K, Ensini, M, Goemans, N, De Luca, A, Pereda, A, Hemmings, R, Campion, G, Kaye, E, Arechavala-Gomeza, V, Goyenvalle, A, Niks, E, Veldhuizen, O, Furlong, P, Stoyanova-Beninska, V, Wood, M, Johnson, A, Mercuri, E, Muntoni, F, Sepodes, B, Haas, M, Vroom, E, Aartsma-Rus, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2016
|
Similar Items
-
Splicing modulation therapy in the treatment of genetic diseases
by: Arechavala-Gomeza V, et al.
Published: (2014-12-01) -
Delivery is key: lessons learnt from developing splice-switching antisense therapies
by: Godfrey, C, et al.
Published: (2017) -
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
by: Cirak, S, et al.
Published: (2011) -
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
by: Cirak, S, et al.
Published: (2011) -
THE CLINICAL PHENOTYPIC SPECTRUM OF GFPT1 ASSOCIATED CONGENITAL MYASTHENIC SYNDROME
by: Chaouch, A, et al.
Published: (2012)